Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00677079 · ClinicalTrials.gov registry record · Phase 2
Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase 2 study of Primary Peritoneal Cancer and Advanced Epithelial Ovarian Cancer, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT00677079 is a Phase 2 study of Primary Peritoneal Cancer and Advanced Epithelial Ovarian Cancer that has completed, run by Sanofi. The registered enrollment target is 12 participants, below the 152-participant average among 27 other Primary Peritoneal Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00677079, a Phase 2 study of Primary Peritoneal Cancer and Advanced Epithelial Ovarian Cancer, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study was to determine the efficacy of iniparib (BSI-201/SAR240550) in patients with breast cancer gene-associated (BRCA) ovarian cancer. Up to 35 patients were to be treated using a Simon 2-stage optimal design, i.e. twelve were to be treated in a first stage, then if 2/12 patients responded to treatment as defined by Response Evaluation Criteria in Solid Tumor (RECIST), 23 additional patients were be treated in the second stage.
Conditions Studied
Interventions
- DRUG Iniparib
Study Locations (1)
New York
- - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-06 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00677079
The ClinicalTrials.gov registry entry for NCT00677079 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 152-participant average among 27 other Primary Peritoneal Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Primary Peritoneal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Iniparib is the first listed.
NCT00677079 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00677079 about?
NCT00677079 is a clinical study titled "Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". The goal of this study was to determine the efficacy of iniparib (BSI-201/SAR240550) in patients with breast cancer gene-associated (BRCA) ovarian cancer. Up to 35 patients were to be treated using a Simon 2-stage optimal design, i.e. twelve were to be treated in a first stage, then if 2/12 patient...
What is the current status of trial NCT00677079?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2008-06. Estimated completion is 2008-12.
What conditions does trial NCT00677079 study?
This clinical trial studies the following conditions: Primary Peritoneal Cancer, Advanced Epithelial Ovarian Cancer.
What interventions are being tested in trial NCT00677079?
The interventions under investigation include: Iniparib (DRUG).
Who is sponsoring clinical trial NCT00677079?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00677079 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Peritoneal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RECRUITING · Phase 2
-
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.